← Leaderboards
Nolan R. Williams
Magnus Medical Inc
$10,469,756
Attributed
$19,475,715
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.4M · FY2016–25$10M$7.5M$5M$2.5M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,475,715 · 6
By mechanism
UG3$9,001,560 · 2
R01$8,162,155 · 3
R33$2,312,000 · 1
Top collaborators
- Raag D Airan6 shared
- Conor M Liston4 shared
- Brandon S Bentzley3 shared
- Faith M. Gunning3 shared
- David Spiegel3 shared
- James Warren Murrough1 shared
- Benjamin Zebley1 shared
Others in their field
Top investigators on “Brain”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Michael W Weiner · Northern California Institute Res &Educ$149,959,854
- David A Bennett · Rush University Medical Center$148,375,056
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$114,442,832
- Hongkui Zeng · Allen Institute$113,960,965
Research focus
BrainRestAnteriorNeuroregulationCingulate CortexResponseDisease RemissionFunctional Magnetic Resonance ImagingRepetitive Transcranial Magnetic StimulationLeftPrefrontal CortexMental DepressionTreatment-Resistant DepressionDepressive SymptomsPatternSide EffectNeural CircuitDoseKetamineFda ApprovedTechnologyNeurobiologyInnovationProtocols Documentation
Grant awards (24)
Clinical Translation of Ultrasonic Ketamine Uncaging for Non-Opioid Therapy of Chronic Pain$1,318,377
UG3 · FY2025 · NS
Clinical Translation of Ultrasonic Ketamine Uncaging for Non-Opioid Therapy of Chronic Pain$19,301
UG3 · FY2025 · NS
Biomarker-Guided Antidepressant Selection for Treatment-Resistant Depression$1,377,361
UG3 · FY2024 · MH
Efficacy of biomarker-guided rTMS for treatment resistant depression$1,307,136
R01 · FY2024 · MH
The Effects of Stanford Accelerated Intelligent Neuromodulation Therapy on Explicit and Implicit Suicidal Cognition$377,647
R01 · FY2024 · MH
Utilizing changes in human brain connectivity to establish a dose-response relationship involved in the therapeutic actions of prefrontal brain stimulation on depression symptoms$343,374
R01 · FY2024 · MH · contact PI
Clinical Translation of Ultrasonic Ketamine Uncaging for Non-Opioid Therapy of Chronic Pain$129,968
UG3 · FY2024 · NS
The Effects of Stanford Accelerated Intelligent Neuromodulation Therapy on Explicit and Implicit Suicidal Cognition$86,807
R01 · FY2024 · MH
Clinical Translation of Ultrasonic Ketamine Uncaging for Non-Opioid Therapy of Chronic Pain$3,041,068
UG3 · FY2023 · NS
Efficacy of biomarker-guided rTMS for treatment resistant depression$1,307,136
R01 · FY2023 · MH
Utilizing changes in human brain connectivity to establish a dose-response relationship involved in the therapeutic actions of prefrontal brain stimulation on depression symptoms$490,922
R01 · FY2023 · MH · contact PI
The Effects of Stanford Accelerated Intelligent Neuromodulation Therapy on Explicit and Implicit Suicidal Cognition$399,033
R01 · FY2023 · MH
Utilizing changes in human brain connectivity to establish a dose-response relationship involved in the therapeutic actions of prefrontal brain stimulation on depression symptoms$117,008
R01 · FY2023 · MH · contact PI
Utilizing changes in human brain connectivity to establish a dose-response relationship involved in the therapeutic actions of prefrontal brain stimulation on depression symptoms$117,008
R01 · FY2022 · MH · contact PI
Clinical Translation of Ultrasonic Ketamine Uncaging for Non-Opioid Therapy of Chronic Pain$1,697,084
UG3 · FY2021 · NS
The Effects of Stanford Accelerated Intelligent Neuromodulation Therapy on Explicit and Implicit Suicidal Cognition$619,242
R01 · FY2021 · MH · contact PI
Utilizing changes in human brain connectivity to establish a dose-response relationship involved in the therapeutic actions of prefrontal brain stimulation on depression symptoms$555,754
R01 · FY2021 · MH · contact PI
The Effects of Stanford Accelerated Intelligent Neuromodulation Therapy on Explicit and Implicit Suicidal Cognition$630,597
R01 · FY2020 · MH · contact PI
Utilizing changes in human brain connectivity to establish a dose-response relationship involved in the therapeutic actions of prefrontal brain stimulation on depression symptoms$565,120
R01 · FY2020 · MH · contact PI
Clinical Translation of Ultrasonic Ketamine Uncaging for Non-Opioid Therapy of Chronic Pain$1,418,401
UG3 · FY2019 · NS
Efficacy of biomarker-guided rTMS for treatment resistant depression$1,245,371
R01 · FY2019 · MH
Use of Repetitive Transcranial Magnetic Stimulation to Augment Hypnotic Analgesia$790,000
R33 · FY2018 · AT · contact PI
Use of Repetitive Transcranial Magnetic Stimulation to Augment Hypnotic Analgesia$790,000
R33 · FY2017 · AT · contact PI
Use of Repetitive Transcranial Magnetic Stimulation to Augment Hypnotic Analgesia$732,000
R33 · FY2016 · AT · contact PI